An Taoiseach, Simon Harris, TD, und Robert Ford, Chairman und Chief Executive Officer von Abbott, nehmen an der offiziellen Eröffnung teilÜber 800 Mitarbeiter sollen in der Produktionsstätte für Diabetes-Technologie beschäftigt werden, die Teil einer 440-Millionen-Euro-Investition ist, die Abbott an zwei Standorten in Irland tätigt.Die Anlage wird die weltweit höchste Produktion von FreeStyle Libre® Sensoren haben

KILKENNY, Irland, 18. November 2024 /PRNewswire/ -- Abbott (NYSE: ABT) hat heute seine hochmoderne Produktionsstätte in Kilkenny, Irland, in Anwesenheit des irischen Premierministers Simon Harris und des Chairman und Chief Executive Officer von Abbott, Robert Ford, feierlich eröffnet. Der Standort ist ein globales Produktionszentrum für Abbotts Geschäftsbereich Diabetes Care und wird mehr als 800 Mitarbeiter beschäftigen.

An Taoiseach, Simon Harris, TD, and Abbott Chairman and Chief Executive Officer, Robert Ford, attend official openingOver 800 to be employed at the diabetes technology manufacturing site, which is part of a €440 million investment Abbott is making across two sites in IrelandFacility will have the highest production of FreeStyle Libre® sensors in the world

KILKENNY, Ireland, Nov. 18, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today marked the official opening of its state-of-the-art manufacturing facility in Kilkenny, Ireland with a ceremony attended by An Taoiseach, Simon Harris, TD, and Abbott Chairman and Chief Executive Officer, Robert Ford. The site is a global manufacturing centre of excellence for Abbott's diabetes care business and will employ more than 800 people.

Canadians living with type 2 diabetes agree that uplifting words, positive feedback and supportive tools are the most powerful motivators

MISSISSAUGA, ON, Oct. 30, 2024 /CNW/ -- Abbott (NYSE: ABT) today released new data highlighting the emotional challenges faced by people living with type 2 diabetes, revealing key motivators to help them manage their condition.

Nearly 12 million Canadians are living with diabetes or pre-diabetes, and the overwhelming majority have or will be diagnosed with type 2.1 While a variety of factors contribute to the risk of developing type 2 diabetes, it is often positioned to be in someone's control and associated with lifestyle factors, like nutrition and exercise.2 This perception, along with the words and actions of others, can have a profound impact on those navigating the realities of type 2 diabetes.

The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failureTrial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner in their disease progression

ABBOTT PARK, Ill., Oct. 24, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new, first-of-its-kind clinical trial designed to improve outcomes in patients with worsening heart failure who could benefit from advanced therapy options. The TEAM-HF trial, which is planned to enroll up to 850 patients across 75 sites worldwide, will measure pulmonary artery pressures (PAP) using Abbott's CardioMEMS™ HF System to objectively identify advanced heart failure patients at high risk of mortality who could benefit from a life-saving HeartMate 3™ left ventricular assist device (LVAD, or heart pump) earlier in their disease progression.

Sales of $10.6 billion driven by strong underlying base business performance Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digit growth in Medical DevicesContinues to strengthen portfolio with steady cadence of new product approvals, reimbursement coverage, and clinical data

ABBOTT PARK, Ill., Oct. 16, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2024.

Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.21, which excludes specified items.Abbott maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding COVID-19 testing-related sales2.Abbott now projects full-year diluted EPS on a GAAP basis of $3.34 to $3.40 and projects adjusted diluted EPS of $4.64 to $4.70, which represents an increase at the midpoint of the guidance range.In October, Abbott's board of directors authorized a new share repurchase program of up to $7 billion of the company's common shares.In August, Abbott announced a unique global partnership with Medtronic to collaborate on connecting Abbott's world-leading continuous glucose monitoring (CGM) system with Medtronic's insulin delivery devices.In September, Abbott announced the U.S. launch of Lingo™, the company's first continuous glucose monitoring system available without a prescription and designed for people interested in improving their overall health and wellness.In September, Abbott announced a partnership with the Big Ten Conference® to conduct a nationwide blood donation competition to help increase the U.S. blood supply.In September, Abbott completed enrollment ahead of schedule in its VOLT-AF IDE trial, which is designed to evaluate the Volt™ Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib).

Enrollment completed ahead of schedule in the global IDE for Abbott's Volt™ PFA SystemGlobal FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, receives U.S. Food and Drug Administration clearance, begins commercial launch

ABBOTT PARK, Ill., Oct. 10, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has achieved new major milestones to support the company's growing suite of pulsed field ablation (PFA) solutions in electrophysiology: early completion of enrollment in the VOLT-AF IDE Study supporting the Volt™ PFA System, and the launch of the FOCALFLEX trial to assess the company's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (SE), which will be used in the treatment of patients with paroxysmal atrial fibrillation. Together, these two studies represent significant advances for the future of two Abbott PFA catheters, which are being developed as important tools for physicians treating people with abnormal heart rhythms like atrial fibrillation (AFib).

To help address the greatest need for blood in a generation, Abbott, a global leader in blood testing, and the Big Ten Conference are teaming up to host the first college conference-wide blood donation competitionThe school that drives the most blood donations during the 2024 football season will be honored by Abbott at the Discover Big Ten Football Championship Game with a $1 million donation to the school to advance student or community healthStudents, alumni and fans can donate blood on behalf of any of the 18 member schools at blood centers across the country; donation totals will be tracked live at BigTen.Org/Abbott throughout the campaignParticipants receive a free one-month subscription to B1G+ streaming service and are entered to win two tickets and a trip to the Big Ten Football Championship Game

ABBOTT PARK, Ill., Sept. 25, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2024 financial results on Wednesday, Oct. 16, before the market opens. 

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.

About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

ABBOTT PARK, Ill., Sept. 19, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.

This marks the 403rd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2024, to shareholders of record at the close of business on Oct. 15, 2024.

Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.

Designed for people interested in improving their overall health and wellnessProvides real-time glucose data and personal coaching insights based on the body's reaction to nutrition, exercise and life's daily stressorsAvailable without a prescription; explore different purchase options at www.hellolingo.com  

ABBOTT PARK, Ill., Sept. 5, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced U.S. availability of Lingo™, the company's first continuous glucose monitoring system available without a prescription. The Lingo system includes a biosensor and a mobile app designed for consumers who want to improve their overall health and wellness. Lingo is based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by more than 6 million people with diabetes globally1.

The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant depression (TRD) as an option to improve the lives of people with this debilitating conditionApproximately 2.8 million Americans each year are diagnosed with TRD, a form of major depressive disorder that has not responded to two or more treatments1 

ABBOTT PARK, Ill., Sept. 4, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep brain stimulation (DBS) system to manage treatment-resistant depression (TRD), a form of major depressive disorder. The U.S. Food and Drug Administration (FDA) granted Abbott Breakthrough Device designation to explore use of DBS for TRD under its Breakthrough Devices Program, which expedites the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions.

Pure Bliss™ Organic and Pure Bliss Organic with A2 Milk infant formulas – both USDA-certified – are now part of the Pure Bliss by Similac® line that includes European-made Pure Bliss Irish Farms, which starts with fresh milk from cows in IrelandPure Bliss Organic in the 2-fluid ounce ready-to-feed bottle is the only USDA-certified organic liquid infant formula offered in select U.S. retail storesPure Bliss by Similac delivers a selection of organic or European-made infant formulas that provide gentle, complete nutrition and specifically sourced ingredients

Abbott's AVEIR™ DR leadless pacemaker system was first implanted at the Montreal Heart Institute in Montreal, Quebec and Foothills Medical Centre in Calgary, AlbertaThe AVEIR DR leadless pacemaker system is designed to address abnormal heart rhythms 1Abbott's first-of-its-kind i2i™ technology enables synchronized communication between two leadless pacemakers, which are each roughly one-tenth the size of a traditional pacemaker1

MONTREAL, Aug. 15, 2024 /CNW/ -- Abbott (NYSE: ABT) today announced that the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker system that treats people with abnormal or slow heart rhythms,1 has been implanted for the first time at the Montreal Heart Institute, in Montreal, Quebec and Foothills Medical Centre in Calgary, Alberta.

MISSISSAUGA, ON, Aug. 8, 2024 /CNW/ -- Abbott (NYSE: ABT) today announced that the Government of Quebec's Régie de l'assurance maladie du Québec (RAMQ) published an update to its formulary that includes expanded reimbursement for Abbott's FreeStyle Libre 2* flash glucose monitoring system to more adults living with type 1 and type 2 diabetes. 

As of July 4, 2024, provincial reimbursement criteria expanded for individuals 18 years of age and older with type 1 or type 2 diabetes who are treated with intensive insulin to include those who also meet one or more of the following criteria: Those who have not been able to achieve their targeted hemoglobin A1c (HbA1c) or who are unable to recognize or report symptoms of hypoglycemia.   

Sales of $10.4 billion driven by strong underlying base business performance Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digit growth in Medical DevicesContinues to strengthen portfolio with new product approvals

ABBOTT PARK, Ill., July 18, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2024.

Second-quarter GAAP diluted EPS of $0.74 and adjusted diluted EPS of $1.14, which excludes specified items.Abbott raised its full-year 2024 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.30 to $3.40 and projects adjusted diluted EPS of $4.61 to $4.71.Abbott narrowed its full-year 2024 organic sales growth guidance range, excluding COVID-19 testing-related sales, to 9.5% to 10.0%, which represents an increase at the midpoint of the range2.In April, Abbott announced U.S. Food and Drug Administration (FDA) approval of the Esprit™ below-the-knee (BTK) system, a breakthrough innovation for people living with peripheral artery disease. This system is designed to keep arteries open and deliver a drug to support vessel healing prior to completely dissolving.In June, Abbott announced U.S. FDA clearance for two new over-the-counter continuous glucose monitoring systems — Lingo™ and Libre Rio™, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology3.In June, Abbott obtained CE Mark for its AVEIR® dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker system that treats people with abnormal or slow heart rhythms.During the first half of 2024, Abbott announced 10 new growth opportunities coming from the company's highly productive R&D pipeline. These include a combination of new product approvals and new treatment indications.